<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2794">
  <stage>Registered</stage>
  <submitdate>28/05/2010</submitdate>
  <approvaldate>28/05/2010</approvaldate>
  <nctid>NCT01134549</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers</studytitle>
    <scientifictitle>A Double-Blind, Randomized, Placebo-Controlled, Rising Single Intravenous Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of KAI-4169 in Healthy Male Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20130107</secondaryid>
    <secondaryid>KAI-4169-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hyperparathyroidism, Secondary</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other endocrine disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Etelcalcetide
Treatment: drugs - Placebo

Placebo Comparator: Placebo - Participants received a single dose of placebo intravenous injection.

Experimental: Etelcalcetide - Participants received a single dose of etelcalcetide intravenous injection; the starting dose was 0.5 mg.


Treatment: drugs: Etelcalcetide
Administered as a single intravenous (IV) injection

Treatment: drugs: Placebo
Administered as a single intravenous (IV) injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Participants With Adverse Events</outcome>
      <timepoint>From the first dose of study drug through 7 days.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Serum Parathyroid Hormone</outcome>
      <timepoint>Baseline and 10 minutes, 30 minutes, 1 hour, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42 and 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Plasma Ionized Calcium</outcome>
      <timepoint>Baseline and 10 minutes, 30 minutes, 1 hour, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42 and 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Serum Total Calcium</outcome>
      <timepoint>Baseline and 10 minutes, 30 minutes, 1 hour, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42 and 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Serum Corrected Calcium</outcome>
      <timepoint>Baseline and 10 minutes, 30 minutes, 1 hour, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42 and 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Serum Phosphate</outcome>
      <timepoint>Baseline and 10 minutes, 30 minutes, 1 hour, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42 and 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Serum Calcitonin</outcome>
      <timepoint>Baseline and 10 minutes, 30 minutes, 3, 12, 24, and 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Serum 1,25 (OH)2 Vitamin D</outcome>
      <timepoint>Baseline and 12, 24, and 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum Observed Concentration (Cmax) for Etelcalcetide - Plasma samples were analyzed for levels of etelcalcetide for pharmacokinetic (PK) analysis using a validated liquid chromatography/mass spectrometry (LC/MS) method.</outcome>
      <timepoint>Blood samples for PK assessment were drawn pre-dose, at 5, 10, 15, 20, and 30 minutes, post-dose, and at 1, 1.5, 2, 2.5, 3, 4, 6, 12, 24, 36, and 48 hours after drug administration.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area Under the Concentration-time Curve Between the Time of Dose and the Last Time Point (AUCall) for Etelcalcetide</outcome>
      <timepoint>Blood samples for PK assessment were drawn pre-dose, at 5, 10, 15, 20, and 30 minutes, post-dose, and at 1, 1.5, 2, 2.5, 3, 4, 6, 12, 24, 36, and 48 hours after drug administration.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Observed Area Under the Concentration-time Curve Extrapolated to Infinity (AUCINFobs) for Etelcalcetide</outcome>
      <timepoint>Blood samples for PK assessment were drawn pre-dose, at 5, 10, 15, 20, and 30 minutes, post-dose, and at 1, 1.5, 2, 2.5, 3, 4, 6, 12, 24, 36, and 48 hours after drug administration.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Observed Area Under the Concentration-time Curve Extrapolated to Infinity Resulting From Extrapolation to Concentration of 0 ng/mL (AUC%Extrapobs)</outcome>
      <timepoint>Blood samples for PK assessment were drawn pre-dose, at 5, 10, 15, 20, and 30 minutes, post-dose, and at 1, 1.5, 2, 2.5, 3, 4, 6, 12, 24, 36, and 48 hours after drug administration.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Terminal Elimination Rate Constant (?z) for Etelcalcetide</outcome>
      <timepoint>Blood samples for PK assessment were drawn pre-dose, at 5, 10, 15, 20, and 30 minutes, post-dose, and at 1, 1.5, 2, 2.5, 3, 4, 6, 12, 24, 36, and 48 hours after drug administration.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Half-life Associated With the Terminal (Log-linear) Elimination Phase (HL?z) for Etelcalcetide</outcome>
      <timepoint>Blood samples for PK assessment were drawn pre-dose, at 5, 10, 15, 20, and 30 minutes, post-dose, and at 1, 1.5, 2, 2.5, 3, 4, 6, 12, 24, 36, and 48 hours after drug administration.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Body Clearance (CL) for Etelcalcetide</outcome>
      <timepoint>Blood samples for PK assessment were drawn pre-dose, at 5, 10, 15, 20, and 30 minutes, post-dose, and at 1, 1.5, 2, 2.5, 3, 4, 6, 12, 24, 36, and 48 hours after drug administration.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Volume of Distribution at Steady State for Etelcalcetide</outcome>
      <timepoint>Blood samples for PK assessment were drawn pre-dose, at 5, 10, 15, 20, and 30 minutes, post-dose, and at 1, 1.5, 2, 2.5, 3, 4, 6, 12, 24, 36, and 48 hours after drug administration.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Antibodies to Etelcalcetide - Serum samples were analyzed for antibodies against etelcalcetide using a validated enzyme-linked immunosorbent assay (ELISA).</outcome>
      <timepoint>Samples for antibody analysis were collected pre-dose and between days 7-12 and days 21-28.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male between 18 and 45 years of age who have provided written informed consent

          -  Subject is judged to be in good health based on medical history, physical examination,
             and routine laboratory tests</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History or presence of any significant acute or chronic illness (e.g., cardiovascular,
             pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic,
             dermatologic, or neurologic disease) according to the investigator

          -  History of any ongoing medical condition requiring treatment with prescription
             medication

          -  History of asthma, severe allergies including skin reactions or prior anaphylactic
             type reactions

          -  Clinically significant abnormalities on screening clinical examination or laboratory
             safety tests

          -  History of drug or alcohol abuse</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>9/06/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>32</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/07/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>KAI Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Nucleus Network Ltd</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to characterize the safety and tolerability of etelcalcetide in
      healthy young males.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01134549</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>M D</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>